Squarepoint
BBIO icon

Squarepoint’s BridgeBio Pharma BBIO Stock Holding History

Squarepoint’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.8M Buy
1,191,732
+635,408
+114% +$44.5M 0.1% 193
2026
Q1 		$41.3M Buy
556,324
+287,425
+107% +$20.8M 0.05% 390
2025
Q4 		$20.6M Buy
+268,899
New +$17.7M 0.02% 727
2024
Q3 		– Sell
-252,793
Closed -$6.4M – 4110
2024
Q2 		$6.4M Buy
+252,793
New +$6.91M 0.01% 1212
2024
Q1 		– Sell
-79,999
Closed -$3.23M – 4020
2023
Q4 		$3.23M Sell
79,999
-87,527
-52% -$2.63M 0.01% 1676
2023
Q3 		$4.42M Sell
167,526
-89,572
-35% -$2.54M 0.01% 1255
2023
Q2 		$4.42M Buy
257,098
+9,530
+4% +$143K 0.01% 1142
2023
Q1 		$4.1M Buy
247,568
+210,814
+574% +$2.46M 0.02% 987
2022
Q4 		$280K Sell
36,754
-248,912
-87% -$2.38M ﹤0.01% 2612
2022
Q3 		$2.84M Buy
285,666
+165,973
+139% +$1.72M 0.01% 1083
2022
Q2 		$1.09M Sell
119,693
-23,489
-16% -$196K 0.01% 1547
2022
Q1 		$1.45M Buy
143,182
+54,711
+62% +$561K 0.01% 1356
2021
Q4 		$1.48M Buy
88,471
+43,896
+98% +$1.86M ﹤0.01% 1445
2021
Q3 		$2.09M Buy
44,575
+2,692
+6% +$144K 0.01% 1179
2021
Q2 		$2.55M Buy
41,883
+19,755
+89% +$1.13M 0.01% 1051
2021
Q1 		$1.36M Buy
22,128
+1,806
+9% +$118K 0.01% 1293
2020
Q4 		$1.45M Buy
20,322
+4,727
+30% +$228K 0.01% 1112
2020
Q3 		$585K Sell
15,595
-1,741
-10% -$54.8K 0.01% 1313
2020
Q2 		$565K Buy
+17,336
New +$528K 0.01% 1251

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Squarepoint's BBIO Position: Q2 2026 in Review

Squarepoint increased its BridgeBio Pharma (BBIO) stake by 114% in Q2 2026, buying an estimated $44.5M and bringing the position to 1,191,732 shares worth $88.8M. The position accounts for 0.1% of the portfolio, ranked #193.

Squarepoint first reported a position in BBIO in Q2 2020 and has held it in 19 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Squarepoint held 1,191,732 shares of BridgeBio Pharma worth $88.8M as of Q2 2026.
  • Squarepoint bought 635,408 BridgeBio Pharma shares in Q2 2026, an estimated $44.5M.
  • BridgeBio Pharma made up 0.1% of Squarepoint's portfolio in Q2 2026, its #193 holding.
  • Squarepoint first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 19 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.